Australian consumer healthcare company Wellnex Life plans to list on the London Stock Exchange in two stages to drive domestic and international growth.
The move is supported by partnerships with Haleon for distribution in the Middle East and Europe and an exclusive agreement with Homart Pharmaceuticals for Asian market distribution.
The dual listing aims to expand Wellnex's investor base, boost international presence, and increase shareholder value.
The move aligns with Wellnex's strategy to capitalise on existing international agreements following domestic brand launches and the Pain Away brand acquisition.